References of "De Witte, T"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailUnrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia : a survey on behalf of Eurocord and CLWP of EBMT
Robin, M.; Sanz, G. F.; Ionescu, I. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2011), 25

Detailed reference viewed: 12 (3 ULg)
Full Text
Peer Reviewed
See detailStem cell transplantation in ALL : a donor versus no donor comparison in the EORTC ALL-4 study
Labar, Boris; Suciu, S.; Muus, P. et al

in Leukemia Research (2007)

Detailed reference viewed: 19 (4 ULg)
Full Text
Peer Reviewed
See detailNon-infusional vs intravenous consolidation chemotherapy in eldery patients with acute myeloid leukemia : final results of th EORTC-GIMAMA AML-13 randomized phase III trial
Jehn, U.; Suciu, S.; Thomas, X. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2006), 20

Detailed reference viewed: 28 (4 ULg)
Full Text
Peer Reviewed
See detailThe stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial
Keating, S.; Suciu, S.; de Witte, T. et al

in Leukemia (2003), 17(1), 60-67

Variable numbers of CD34(+) cells can be harvested from the blood of AML patients in CR after G-CSF supported mobilization following consolidation chemotherapy. We hypothesized that a decreased ability to ... [more ▼]

Variable numbers of CD34(+) cells can be harvested from the blood of AML patients in CR after G-CSF supported mobilization following consolidation chemotherapy. We hypothesized that a decreased ability to mobilize stem cells reflects a chemotherapy-induced reduction in the number of normal and leukemic stem cells. We therefore analyzed whether the mobilizing capacity of these patients was of prognostic significance. 342 AML-patients in first CR received daily G-CSF from day 20 of the consolidation course and underwent 1-6 aphereses to obtain a minimum dose of 2 x 10(6) CD34(+) cells/kg. Afterwards they were randomized for autologous bone marrow (M) or blood SCT. As a surrogate marker for the mobilizing capacity, the highest yield of CD34(+) cells of a single apheresis was adopted. Patients could be categorized into four groups: no harvest (n = 76), low yield (<1 x 10(6) CD34(+)/kg; n = 50), intermediate yield (1-6.9 x 10(6) CD34(+) cells/kg; n = 128) and high yield ( :7 x 106 CD34+ cells/kg; n = 88). The median follow-up was 3.4 years; 163 relapses and 16 deaths in CR were reported. Autologous blood or BM SCT was performed in 36%, 64%, 81% and 88%, respectively, of the patients assigned to the no harvest, low, intermediate and high CD34(+) yield group. The 3-year disease-free survival rate was 46.7%, 65.0%, 50.4% and 26.9% (P= 0.0002) and the relapse incidence was 47.5%, 30.1%, 43.1% and 71.9% (P < 0.0001). Multivariate Cox's proportional hazards model showed that the CD34(+) yield was the most important independent prognostic variable (P = 0.005) after cytogenetics. Patients with the highest mobilizing capacity have a poor prognosis due to an increased relapse incidence. [less ▲]

Detailed reference viewed: 12 (3 ULg)